13. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deﬁciency. N Engl J Med 2015; 372(26): 2509–2520. 14. Evans RA, Diamond MS, Rech AJ et al. Lack of immunoediting in mur- ine pancreatic cancer reversed with neoantigen. JCI Insight 2016; 1(14): e88328. 15. Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy suc- cess. Science 2015; 350(6257): 158–159. 16. Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486(7403): 400–404. 17. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 2012; 150(2): 251–263. 18. Fujimoto A, Furuta M, Totoki Y et al. Whole-genome mutational land- scape and characterization of noncoding and structural mutations in liver cancer. Nat Genet 2016; 48(5): 500–509. 19. Kandoth C, McLellan MD, Vandin F et al. Mutational landscape and sig- niﬁcance across 12 major cancer types. Nature 2013; 502(7471): 333–339. 20. Zehir A, Benayed R, Shah RH et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23(6): 703–713. 21. Li L, Goedegebuure P, Mardis ER et al. Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers (Basel) 2011; 3(4): 4191–4211. 22. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol 2013; 31: 443–473. 23. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348(6230): 69–74.ReviewAnnals of Oncology xii16 | Li et al. Volume 28 | Supplement 12 | December 2017 24. Cherryholmes GA, Stanton SE, Disis ML. Current methods of epitope identiﬁcation for cancer vaccine design. Vaccine 2015; 33(51):7408–7414. 25. Desai DV, Kulkarni-Kale U. T-cell epitope prediction methods: an over- view. Methods Mol Biol 2014; 1184: 333–364. 26. Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoin- formatics. Open Biol 2013; 3(1): 120139. 27. Singh SP, Mishra BN. Major histocompatibility complex linked data- bases and prediction tools for designing vaccines. Hum Immunol 2016;77(3): 295–306. 28. Backert L, Kohlbacher O. Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med 2015; 7: 119. 29. Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: implica-tions on vaccine development. J Biomed Inform 2015; 53: 405–414. 30. Rammensee H, Bachmann J, Emmerich NP et al. SYFPEITHI: database for MHC ligands and peptide motifs. I mmunogenetics 1999; 50(3–4): 213–219. 31. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163–175. 32. Lundegaard C, Lamberth K, Harndahl M et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I afﬁnities for peptides of length 8-11. Nucleic Acids Res 2008; 36(Suppl 2): W509–W512. 33. Gubin MM, Zhang X, Schuster H et al. Checkpoint blockade cancer immunotherapy targets tumour-speciﬁc mutant antigens. Nature 2014; 515(7528): 577–581.